ALT-803: Clinical Trials

2 active not recruiting, 1 recruiting. 3 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	3	Active not recruiting 2, Recruiting 1
Phase 2	2	Active not recruiting 2

Follow ALT-803: new trials by email Literature Review of ALT-803 trials Research Report on ALT-803

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In N-803, Tislelizumab, Docetaxel - NSCLC Stage IV	Phase 3	Recruiting	ImmunityBio, Inc.	507	2025-10-01	2026-07-27
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Cobalamin, Dexamethasone, Docetaxel - Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma	Phase 2 / Phase 3	Active not recruiting	SWOG Cancer Research Network	82	2022-03-15	2026-05-18
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer N-803 and BCG, N-803 - Bladder Cancer	Phase 2 / Phase 3	Active not recruiting	ImmunityBio, Inc.	190	2017-06-02	2025-10-16

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Lung Neoplasms (1)  ·  Non-Muscle Invasive Bladder Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

ImmunityBio, Inc. (2)  ·  SWOG Cancer Research Network (1)

Countries

United States (3)  ·  Canada (1)  ·  United Kingdom (1)

Top investigators

John M Wrangle (1)  ·  Karim Chamie, MD (1)

Results publications

PMID 38953850, PMID 40956664

NIH funding

U10CA180888 (1)